CompletedNCT00305500
High-dose escitalopram for OCD over 18 weeks
About this title
Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)
Read the official source — NCT00305500Medication studyAges 18–75Israel
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Bat YamSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Abarbanel Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Israel
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00305500
- Official title
Show the full official title
Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bat Yam
Questions about this study
Who is behind this study?
The study sponsor is Abarbanel Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including escitalopram.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
